Answer
Yes, cemiplimab may increase the risk of rejection in solid organ transplant recipients, so its treatment benefit should be weighed against the risk of possible organ rejection.
Sources for this answer
- LIBTAYO 350 mg concentrate for solution for infusion.Regeneron UK Limited · emc · SmPC §4.4 Special warnings and precautions for use · Version 24Document updated
Sources checked